Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Autor: Qin P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA pu.2.qin@gsk.com., Arabacilar P; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Bernard RE; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Bao W; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Olzinski AR; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Guo Y; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Lal H; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Eisennagel SH; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Platchek MC; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Xie W; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Del Rosario J; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Nayal M; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Lu Q; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Roethke T; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Schnackenberg CG; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Wright F; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA., Quaile MP; Preclinical and Translational Imaging, Platform Technology and Science, GlaxoSmithKline, King of Prussia, PA., Halsey WS; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Hughes AM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Sathe GM; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Livi GP; Target and Pathway Validation, Target Sciences, GlaxoSmithKline, King of Prussia, PA., Kirkpatrick RB; Pipeline Future's Group, GlaxoSmithKline, King of Prussia, PA., Qu XA; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA., Rajpal DK; Computational Biology, Projects Clinical Platforms and Sciences, GlaxoSmithKline, King of Prussia, PA., Faelth Savitski M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Bantscheff M; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Joberty G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Bergamini G; Cellzome GmbH, A GSK Company, GlaxoSmithKline, King of Prussia, PA., Force TL; Basic & Translational Research, School of Medicine, Vanderbilt University, Nashville, TN., Gatto GJ Jr; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Hu E; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA., Willette RN; Heart Failure Discovery Performance Unit, Metabolic Pathways and Cardiovascular Therapy Area GlaxoSmithKline, King of Prussia, PA.

Publikováno v: Journal of the American Heart Association [J Am Heart Assoc] 2017 May 09; Vol. 6 (5). Date of Electronic Publication: 2017 May 09.

An initial characterization of N-terminal-proatrial natriuretic peptide in serum of Sprague Dawley rats.

Autor: Colton HM; Safety Assessment, Platform Technology & Science, Medicines Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. heidi.m.colton@gsk.com, Stokes AH, Yoon LW, Quaile MP, Novak PJ, Falls JG, Kimbrough CL, Cariello NF, Jordan HL, Berridge BR

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2011 Apr; Vol. 120 (2), pp. 262-8. Date of Electronic Publication: 2011 Jan 17.

Direct inotropic effects of exogenous and endogenous urotensin-II: divergent actions in failing and nonfailing human myocardium.

Autor: Quaile MP; Department of Physiology, Temple University School of Medicine, Philadelphia, Pa, USA., Kubo H, Kimbrough CL, Douglas SA, Margulies KB

Publikováno v: Circulation. Heart failure [Circ Heart Fail] 2009 Jan; Vol. 2 (1), pp. 39-46.

Reduced sarcoplasmic reticulum Ca(2+) load mediates impaired contractile reserve in right ventricular pressure overload.

Autor: Quaile MP; Department of Physiology and the Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, USA., Rossman EI, Berretta RM, Bratinov G, Kubo H, Houser SR, Margulies KB

Publikováno v: Journal of molecular and cellular cardiology [J Mol Cell Cardiol] 2007 Nov; Vol. 43 (5), pp. 552-63. Date of Electronic Publication: 2007 Sep 06.